
Last year in the UK over 60,000 cancer patients enrolled on clinical trials aimed at improving cancer treatments and making them available to all.
This study is looking at developing new treatments for myeloma, lymphoma, leukaemia and some other blood cancers in the laboratory.
Myeloma, lymphoma and leukaemia are all types of blood cancers.
In this study, doctors want to use some of the cells from your blood and bone marrow to test the new treatment in the laboratory.
They also want blood and bone marrow from healthy volunteers who do not have a blood cancer
The aims of this study are to:
You may be able to enter this trial if you:
You might be able to join as a healthy volunteer if you do not have a blood cancer, are at least 18 years old and the following also apply.
You cannot enter this trial if you:
This study will recruit 500 people with blood cancer and 100 people without.
Everybody taking part will have a blood test and bone marrow test once a year for 5 years.
If you have blood cancer, there are no extra hospital visits as part of this trial. You give blood and bone marrow samples when you see the doctor as part of your routine care.
If you are a healthy volunteer the doctors will organise your visit at a time convenient for you.
Side effects of bone marrow tests include discomfort and bruising at your biopsy site. You may need some mild painkillers to take home or the doctor may suggest you take paracetamol. Very rarely you may also have bleeding, infection and pain.
You may have a small bruise where you had your blood test.
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Guido Franzoso
Imperial College Healthcare NHS Trust
Medical Research Council (MRC)
NIHR Clinical Research Network: Cancer
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040
Last year in the UK over 60,000 cancer patients enrolled on clinical trials aimed at improving cancer treatments and making them available to all.